Viridian Therapeutics, Inc. (VRDN)
NASDAQ: VRDN · Real-Time Price · USD
16.61
-0.39 (-2.29%)
At close: May 8, 2026, 4:00 PM EDT
16.52
-0.09 (-0.52%)
After-hours: May 8, 2026, 7:46 PM EDT
Viridian Therapeutics Revenue
Viridian Therapeutics had revenue of $141.00K in the quarter ending March 31, 2026, with 95.83% growth. This brings the company's revenue in the last twelve months to $70.92M, up 23,382.78% year-over-year. In the year 2025, Viridian Therapeutics had annual revenue of $70.85M with 23,359.93% growth.
Revenue (ttm)
$70.92M
Revenue Growth
+23,382.78%
P/S Ratio
24.14
Revenue / Employee
$281,421
Employees
252
Market Cap
1.71B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 70.85M | 70.55M | 23,359.93% |
| Dec 31, 2024 | 302.00K | -12.00K | -3.82% |
| Dec 31, 2023 | 314.00K | -1.46M | -82.28% |
| Dec 31, 2022 | 1.77M | -1.19M | -40.20% |
| Dec 31, 2021 | 2.96M | 1.91M | 182.19% |
| Dec 31, 2020 | 1.05M | -3.41M | -76.46% |
| Dec 31, 2019 | 4.46M | -3.93M | -46.80% |
| Dec 31, 2018 | 8.39M | 4.38M | 109.49% |
| Dec 31, 2017 | 4.00M | 526.00K | 15.13% |
| Dec 31, 2016 | 3.48M | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Ardelyx | 427.68M |
| Innoviva | 420.69M |
| Vericel | 292.09M |
| Nuvation Bio | 143.05M |
| Zymeworks | 81.26M |
| Nurix Therapeutics | 71.78M |
| Recursion Pharmaceuticals | 66.41M |
| Generate Biomedicines | 30.30M |
VRDN News
- 2 days ago - Viridian Therapeutics 7.353M share Spot Secondary priced at $17.00 - TheFly
- 3 days ago - Viridian Therapeutics price target raised to $34 from $30 at RBC Capital - TheFly
- 3 days ago - Viridian Therapeutics Announces Pricing of Upsized Concurrent Public Offerings of 1.75% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $350.0 Million - Business Wire
- 4 days ago - Viridian Therapeutics Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032, Common Stock and Series B Non-Voting Convertible Preferred Stock - Business Wire
- 4 days ago - Viridian Therapeutics Transcript: Study result - Transcripts
- 4 days ago - Viridian announces REVEAL-2 phase 3 study met primary endpoint - TheFly
- 4 days ago - Viridian Therapeutics reports Q1 EPS (90c), consensus ($1.09) - TheFly
- 5 days ago - Viridian eye disease drug benefits chronic patients in late-stage trial - Reuters